InSilico Medicine Cayman (HKG: 03696) key facts
- InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms.
- InSilico Medicine Cayman (HKG: 03696)’s last known valuation is $1.7B (Dec 2025).
- It has raised $841.9M across 6 recorded rounds; the latest was Series E extension (final close) ($13.0M) in Jun 2025.
- Notable investors include Hongshan Capital Group, F-Prime Capital, Qiming Venture Partners, Eight Roads, Aramco Ventures — 50 tracked in total.
- Status: Publicly Held.
InSilico Medicine Cayman (HKG: 03696) leadership
- Alex ZhavoronkovFounder, Chairman of the Board & CEO
- Feng RenCo-CEO, Chief Scientific Officer & Executive Director
- Alex AliperPresident
Who backs InSilico Medicine Cayman (HKG: 03696)
50+- ·The complete investor list: 50 names
- ·Watch InSilico Medicine Cayman (HKG: 03696): the Monday email on marks, rounds and moves
InSilico Medicine Cayman (HKG: 03696) funding rounds
6 roundsInSilico Medicine Cayman (HKG: 03696) valuation
InSilico Medicine Cayman (HKG: 03696) is now publicly traded; this page covers its private-market history, where its last recorded valuation was $1.7 billion (Dec 2025). Secondary trades, fund marks and rounds below are the private-market record; the listed share price is not tracked here.
How much has InSilico Medicine Cayman (HKG: 03696) raised?
InSilico Medicine Cayman (HKG: 03696) has raised $842 million across 6 recorded rounds since 2019. The largest was a $60 million Series D in Jun 2022; the most recent was a $13 million Series E extension (final close) in Jun 2025.
InSilico Medicine Cayman (HKG: 03696) investors
50 investors are on record for InSilico Medicine Cayman (HKG: 03696), including Hongshan Capital Group, F-Prime Capital, Qiming Venture Partners and Eight Roads. By type, the record holds 9 venture capital firms and 3 asset managers.
Who runs InSilico Medicine Cayman (HKG: 03696)
5 people are listed on the InSilico Medicine Cayman (HKG: 03696) team: 3 executives and 2 board members, including Alex Zhavoronkov (Founder) and Feng Ren (Co-CEO). 2 of them have a verified direct contact on file.
Comparable companies
Comparable biotech names by valuation on PrivateMarketView: Xaira Therapeutics ($3.5 billion), Chai Discovery ($1.3 billion) and Merida Biosciences ($228 million).
About InSilico Medicine Cayman (HKG: 03696)
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from Hong Kong.
- Industry
- Biotech
- Sector
- Healthcare
- HQ
- Hong Kong, MA, Hong Kong
- Founded
- 2014
- Employees
- 317
- Website
- insilico.com/
- Ownership
- Publicly Held
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
InSilico Medicine Cayman (HKG: 03696)’s last known valuation, Dec 2025. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.